Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107, for…
The study's primary objective is to assess the safety and tolerability of SUVN-I6107, a true muscarinic M1 positive allosteric…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.